BR Biopharma (NASDAQ:BRBI – Get Free Report) is one of 1,748 publicly-traded companies in the “Capital Markets” industry, but how does it weigh in compared to its peers? We will compare BR Biopharma to similar companies based on the strength of its valuation, risk, institutional ownership, dividends, earnings, profitability and analyst recommendations.
Earnings & Valuation
This table compares BR Biopharma and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BR Biopharma | $2.23 billion | $31.36 million | 137.25 |
| BR Biopharma Competitors | $29.07 billion | $396.21 million | 8.27 |
BR Biopharma’s peers have higher revenue and earnings than BR Biopharma. BR Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BR Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| BR Biopharma Competitors | 5376 | 19723 | 21910 | 614 | 2.37 |
As a group, “Capital Markets” companies have a potential upside of 27.89%. Given BR Biopharma’s peers stronger consensus rating and higher probable upside, analysts clearly believe BR Biopharma has less favorable growth aspects than its peers.
Dividends
BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.8%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Capital Markets” companies pay a dividend yield of 3.2% and pay out 30.7% of their earnings in the form of a dividend.
Insider and Institutional Ownership
30.5% of shares of all “Capital Markets” companies are owned by institutional investors. 29.4% of BR Biopharma shares are owned by insiders. Comparatively, 13.0% of shares of all “Capital Markets” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares BR Biopharma and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BR Biopharma | N/A | N/A | N/A |
| BR Biopharma Competitors | 267.88% | 78.15% | 3.52% |
Summary
BR Biopharma peers beat BR Biopharma on 11 of the 14 factors compared.
BR Biopharma Company Profile
BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.
Receive News & Ratings for BR Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BR Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
